Therapeutic to Reduce Acute Inflammation in Severe Burn Injuries

减轻严重烧伤急性炎症的治疗方法

• 批准号: 7053478
• 负责人: ELISABETH M ALICOT-CARROLL
• 金额: $ 12.92万
• 依托单位: DECIMMUNE THERAPEUTICS, INC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7053478
• 关键词: biotechnology; biotherapeutic agent; burn therapy; burns; disease /disorder model; drug design /synthesis /production; genetically modified animals; immune response; immunocytochemistry; immunoglobulin M; immunopharmacology; immunoregulation; immunosuppressive; inflammation; intravenous administration; laboratory mouse; light microscopy; phenotype; reperfusion; scars; skin disorder chemotherapy; topical drug application; wound healing

DESCRIPTION (provided by applicant): Declmmune Therapeutics is seeking support to develop a therapeutic product that will significantly reduce the debilitating and sometimes life-threatening result of severe burn injuries. Much of the final extent of tissue loss following burn injury is determined by the inflammatory response. The company has developed novel methods and compounds that inhibit inflammation at the initial site of tissue injury and significantly reduce the destruction of tissue surrounding the injury. Preliminary studies in animal models of burn injury have demonstrated a potential protective effect of one of these compounds, preventing the inflammatory destruction of skin tissue following burn trauma, resulting in healing without scarring or loss of hair growth. Over 75,000 patients per year are hospitalized for severe burn injuries, spending an average of two weeks undergoing painful and expensive treatments consisting of antibiotics, nutritionals and surgical care of the wound. The long-term objective of this project is to develop a therapeutic product that reduces the inflammatory destruction of skin tissue following burn injury and improves the outcome of the severely burned patient. Such a therapeutic could result in a wound which heals faster and with less need for skin grafting or other surgical intervention, reduce hospitalization costs and result in less permanent scarring and debilitating effects to the patient. Declmmune has developed compounds which block acute inflammation following ischemia/reperfusion injury in animal models. The objective of this proposal is to test these compounds in a mouse model of thermal burn injury with the following aims: 1) To demonstrate that one or more of these compounds is effective in improving the healing of an acute burn, 2) To determine how long after the burn injury the compound can be administered and be effective, and 3) To determine how severe a burn wound can still show improvement with the compound. The expected endpoint is the demonstration that in our animal model, one or more of these compounds can be administered immediately or shortly after a burn injury, either intravenously or topically, and the burn wound is shown to heal with significantly less scarring and loss of hair growth vs. the untreated animal. Phase II SBIR funding will support the development of the peptide compound into a drug candidate, preclinical testing and clinical evaluation in Phase I human trials.

描述（由申请人提供）：Declmmune Therapeutics正在寻求支持以开发一种治疗产品，该产品将大大减少严重烧伤受伤的衰弱，有时甚至危及生命的结果。烧伤损伤后的最终组织损失的大部分程度取决于炎症反应。该公司开发了新的方法和化合物，可在组织损伤的最初部位抑制炎症，并显着减少损伤周围组织的破坏。在烧伤损伤的动物模型中的初步研究表明，其中一种化合物的潜在保护作用，可防止烧伤创伤后皮肤组织的炎症破坏，导致愈合而不会疤痕或造成头发生长损失。每年超过75,000名患者因严重烧伤而住院，平均需要两周的时间接受疼痛和昂贵的治疗，包括抗生素，营养和伤口手术护理。该项目的长期目标是开发一种治疗产品，可在烧伤后减少皮肤组织的炎症破坏，并改善严重燃烧的患者的结果。这种治疗性可能会导致伤口更快，而对皮肤移植或其他手术干预的需求较少，降低住院费用，并导致对患者的永久性疤痕和衰弱效果较小。 Declmmune开发了在动物模型中缺血/再灌注损伤后阻断急性炎症的化合物。该提案的目的是在热烧伤损伤的小鼠模型中测试这些化合物，其目的：1）证明这些化合物中的一种或多种可以有效地改善急性灼伤的愈合，2）确定烧伤后可以施用和有效的烧伤后的烧伤后多长时间，并确定烧伤能够使烧伤表现出对烧伤的损伤仍然可以表现出该化合物的变化。预期的终点是证明，在我们的动物模型中，这些化合物中的一种或多种可以立即或在烧伤后不久或局部施用，并且烧伤的伤口被证明可以愈合，而疤痕和头发生长的损失明显较小，而无治疗的动物的损失则明显较小。 II期SBIR资金将支持肽化合物在I期人类试验中的临床前测试和临床评估中的开发。